Abstract 4971: IACS-010759, a novel inhibitor of complex I in Phase I clinical development to target OXPHOS dependent tumors

作者
Jennifer R. Molina,Madhavi L. Bandi,Jennifer Bardenhagen,Christopher Aaron Bristow,Christopher Carroll,Edward Q. Chang,Jason B. Cross,Naval Guastad Daver,Ningping Feng,Jason P. Gay,Mary Geck,Jennifer Greer,Jing Dong J Han,Judy Hirst,Sha Huang,Yongying Jiang,Zhijun Kang,Marina Y Konopleva,Gang Liu,Helen Ma
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:77 (13_Supplement): 4971-4971
标识
DOI:10.1158/1538-7445.am2017-4971
摘要

Abstract Tumor cells depend on both glycolysis and oxidative phosphorylation (OXPHOS) for energy and biomass production to support cell proliferation. Recent data has demonstrated a dependence of various tumor types on mitochondrial OXPHOS, which represents an exciting therapeutic opportunity. Through an extensive medicinal chemistry campaign, IACS-010759 was identified as a potent, selective inhibitor of complex I of the electron transport chain, which is orally bioavailable and has excellent PK and physicochemical properties in preclinical species. Our group and others have demonstrated that AML, plus subsets of glioblastoma, neuroblastoma, lymphoma, melanoma, triple negative breast cancer (TNBC) and pancreatic cancer (PDAC) are highly dependent on OXPHOS to meet energy and biomass demands. Treatment of multiple cell lines and patient derived xenograft (PDX) models in several cancer types with IACS-010759 led to a robust decrease in cell viability and often an increase in apoptosis with EC50 values between 1 nM - 50 nM across multiple lines. Through a series of mechanistic studies we established that IACS-10759 blocks complex I of the electron transport at the quinone binding site. Mechanistically, response to IACS-010759 was associated with induction of a metabolic imbalances that negatively impacted energy homeostasis, aspartate biosynthesis, and NTP production due to reduced conversion of NADH to NAD+ by complex I, decreased ATP production, TCA cycle flux and nucleotide biosynthesis. Tumor growth inhibition and regression have been observed in molecularly defined subsets of TNBC and PDAC PDX xenograft models treated with IACS-010759, indicating that subsets of these indications are dependent on OXPHOS. Furthermore, treating TNBC or PDAC PDX models post-chemotherapy with IACS-010759 extends progression free survival, consistent with IACS-010759 targeting recently described metabolically adapted residual tumor cells. In orthotopic xenograft models of primary AML cells, daily oral treatment with 1-7.5 mg/kg IACS-010759 extended the median survival. Efficacy was paralleled by robust modulation of OCR, aspartate, and a gene signature levels. Therefore, these readouts (OCR, aspartate and a nanostring geneset) have been validated for use as exploratory clinical biology of response endpoints. In parallel, completion of preclinical chemistry, manufacturing and control (CMC) as well as GLP safety and tolerability studies with IACS-010759 in multiple species have enabled the selection of a clinical entry dose. As a result of the robust response in multiple cell lines, primary patient samples, and efficacy in PDX models, a Phase I clinical trial in relapsed, refractory AML was initiated in October 2016, with a parallel trial in solid tumors expected to initiate in early 2017. Initial results from the on-going AML trial will be disclosed. Citation Format: Jennifer Molina, Madhavi Bandi, Jennifer Bardenhagen, Christopher Bristow, Christopher Carroll, Edward Chang, Jason Cross, Naval Daver, Ningping Feng, Jason Gay, Mary Geck Do, Jennifer Greer, Jing Han, Judy Hirst, Sha Huang, Yongying Jiang, Zhijun Kang, Marina Konopleva, Gang Liu, Helen Ma, Polina Matre, Timothy McAfoos, Funda Meric-Bernstam, Pietro Morlacchi, Florian Muller, Marina Protopopova, Melinda Smith, Sonal Sonal, Yuting Sun, Jay Theroff, Andrea Viale, Quanyun Xu, Carlo Toniatti, Giulio Draetta, Philip Jones, M. Emilia Di Francesco, Joseph R. Marszalek. IACS-010759, a novel inhibitor of complex I in Phase I clinical development to target OXPHOS dependent tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4971. doi:10.1158/1538-7445.AM2017-4971

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
繁荣的皮皮虾完成签到,获得积分10
1秒前
2秒前
慕青的应助被Tenax采纳,获得10
2秒前
wanci的应助被丫丫采纳,获得10
2秒前
风吹麦浪的应助被tomatoGG采纳,获得10
3秒前
矜持发布了新的文献求助10
3秒前
思源的应助被一二三采纳,获得10
3秒前
JUNJUN完成签到,获得积分10
3秒前
程诺发布了新的文献求助20
4秒前
蓝天的应助被Herrr采纳,获得10
4秒前
李123完成签到,获得积分10
4秒前
5秒前
5秒前
温暖小霸王完成签到,获得积分10
5秒前
华仔的应助被cyx-buct采纳,获得10
5秒前
大力访文发布了新的文献求助10
6秒前
6秒前
6秒前
波奇朵朵发布了新的文献求助10
7秒前
在水一方的应助被仁爱小松鼠采纳,获得10
7秒前
7秒前
李健的小迷弟的应助被LOAD采纳,获得10
8秒前
Freya完成签到,获得积分10
8秒前
8秒前
涛涛发布了新的文献求助10
8秒前
李123发布了新的文献求助10
8秒前
嘻嘻哈哈的应助被Herrr采纳,获得10
8秒前
李爱国的应助被茶多酚采纳,获得10
10秒前
Akim的应助被匡吉六个日采纳,获得10
10秒前
魂殇发布了新的文献求助20
10秒前
10秒前
皮皮完成签到,获得积分10
11秒前
汉堡包的应助被zuizui采纳,获得10
11秒前
11秒前
欢呼的梦蕊完成签到,获得积分20
11秒前
mochenyun完成签到,获得积分10
11秒前
Ranann发布了新的文献求助10
12秒前
无聊关注了科研通微信公众号
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160632
求助须知:如何正确求助?哪些是违规求助? 9555512
关于积分的说明 21728801
捐赠科研通 7750444
什么是DOI,文献DOI怎么找? 3427429
关于科研通互助平台的介绍 2552456
邀请新用户注册赠送积分活动 2471817